Education
About Us
Working with TipRanks
Follow Us
OnKure Therapeutics (OKUR)
NASDAQ:OKUR
OKUR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.45 - $20.00
Previous CloseN/A
Volume8.61K
Average Volume (3M)33.14K
Market Cap
$67.85M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
May 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.17
Shares Outstanding12,749,299
10 Day Avg. Volume34,071
30 Day Avg. Volume33,137
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$31.75Price Target Upside528.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
OnKure Therapeutics News
See All OKUR News
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentOKI-219 appears to have best-in-class tolerability, observing only Grade 1 TEAEs even at the highest 900mg BID dose and no DLTs.
Market PotentialOKI-219 has the potential to be the first approved mutation-specific PI3Kα inhibitor, being differentiated from competitors.
ValuationWith the stock trading at 50% discount to cash value, there is a favorable risk/reward in owning OKUR.
Bears Say
Investor SentimentShort interest is relatively high at 26% of the float, indicating a significant level of skepticism among investors about the company's prospects.
Market ReactionInvestors reacted negatively following the Phase 1 safety and efficacy data with OKI-219 at SABCS 2024.
Safety ConcernsThere are two key points that are acting against OKUR that needs to be resolved — restricted patient population (H1047R mutant, ~12-20% of met. breast or other cancer types), and if higher dose cohorts of 600 mg and 900 mg BID will show cumulative toxicity.
---
Ownership Overview
8.71% Insiders
0.12% Mutual Funds
0.03% Other Institutional Investors
89.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $4.45 and its highest was $20.00 in the past 12 months.
What is OnKure Therapeutics’s market cap?
OnKure Therapeutics’s market cap is $67.85M.
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 50 days.
How were OnKure Therapeutics’s earnings last quarter?
OnKure Therapeutics released its earnings results on Mar 10, 2025. The company reported -$1.37 earnings per share for the quarter, missing the consensus estimate of -$0.793 by -$0.577.
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 12,749,299 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
OnKure Therapeutics reported an EPS of -$1.37 in its last earnings report, missing expectations of -$0.793. Following the earnings report the stock price went down -0.202%.
Which hedge fund is a major shareholder of OnKure Therapeutics?
Currently, no hedge funds are holding shares in OKUR
---
OnKure Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.75 (528.71% Upside)
$31.75 (528.71% Upside)
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.11%
12-Months-Change
Fundamentals
Return on Equity
-54.74%
Trailing 12-Months
Asset Growth
6.95%
Trailing 12-Months
Company Description
OnKure Therapeutics
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
---
OKUR Stock 12 Month Forecast
Average Price Target
$31.75
▲(528.71% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Crispr Therapeutics AG
―
Allogene Therapeutics
―
Immatics
―
Best Analysts Covering OKUR
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
-1.87%
reiterated a buy rating 11 days ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -1.87% per trade.
---